source
- Senior FDA official overrides reviewers to grant Replimune accelerated approval for melanoma drug TudriqevFDA's primary review team recommended rejecting Replimune's melanoma therapy Tudriqev, saying the company had not adequately addressed key deficiencies noted in earlier complete response letters.…
- Abivax remains independent despite intense acquisition speculationBiotech merger activity is at record levels, yet the French company Abivax, which is developing the ulcerative colitis drug obefazimod, has not been bought. Rumors have floated about a potential $…